The Latest News from Vascular Therapies
Vascular Therapies Completes $25 Million Private Financing
Proceeds to fund ACCESS 2 – a randomized clinical trial evaluating Sirogen TM for improving hemodialysis AV Fistula outcomes in high-risk patients
CRESSKILL, N.J. (Mar. 29, 2022) – Vascular Therapies, Inc. a clinical-stage biopharma company focused on improving vascular access outcomes in patients
with kidney disease, today announced the closing of a $25 million private financing. The financing comprised of existing and new investors, including a Fortune 100 global healthcare company.
Vascular Therapies Announces Presentation of Phase 3 Clinical Trial Results at the American Society of Nephrology Meeting
SirogenTM Shows Encouraging AV Fistula Outcomes in Elderly End-Stage Renal Disease Patients
CRESSKILL, N.J. (Nov.4, 2021) — Vascular Therapies, a privately held biotechnology company is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced the presentation of clinical results from its Phase 3 clinical trial (ACCESS 1) during the Late Breaking Clinical Trials section of the American Association of Nephrology Annual Meeting. The results were presented by Maria DeVita, MD, Senior Nephrologist at Lenox Hill Hospital in New York and Medical Monitor for the study.
Vascular Therapies to Participate in the SVB Leerink 9th Annual Global Healthcare Conference
CRESSKILL, NJ (Feb.11, 2020) – Vascular Therapies, a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, today announced that the company will participate in the SVB Leerink 9th Annual Global Healthcare Conference, taking place February 25-27, 2020, in New York, NY.
Chief Executive Officer, John McDermott, is scheduled to present on Tuesday, February 25, at 1:30 p.m. ET.
Vascular Therapies Completes Upsized $17.3 Million Private Financing
Company funded through 2020. Topline Phase 3 results for Sirogen expected to be announced in Q2 2020
CRESSKILL, NJ (Jan.28, 2020)– Vascular Therapies, a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, today announced the closing of an upsized $17.3 million private financing. The financing comprised existing and new investors, and was increased from an originally targeted $15 million up to $17.3 million, based upon interest from new investors, including a strategic foreign healthcare company.
Vascular Therapies Announces Positive Preliminary Clinical Results from its AV Fistula Trials in Patients with Kidney Disease
CRESSKILL, NJ (Sep. 5, 2019)–Vascular Therapies, a clinical stage biotechnology company, is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local, perivascular drug delivery focused on improving vascular access outcomes in patients with kidney disease. Daniel G. Clair, MD, vascular surgeon and Chairman of the Department of Surgery at Palmetto Health-USC Medical Group in Columbia, South Carolina presented preliminary results from the company’s clinical development program at the recent Eastern Vascular Society Meeting in Pittsburg, Pennsylvania.
Vascular Therapies Announces Completion of Enrollment in the ACCESS Study, a U.S. Phase III Clinical Trial
CRESSKILL, NJ (Aug. 19, 2019)–Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, today announced completion of enrollment in its US Phase III prospective randomized, multicenter, clinical study (ACCESS Trial).
Vascular Therapies Appoints John McDermott as Chief Executive Officer
CRESSKILL, NJ (January 15, 2019) –Vascular Therapies, a biotechnology company focused on improving outcomes for patients with advanced kidney disease today announced the appointment of John McDermott as the Company’s Chief Executive Officer.